Research and Development Partnerships
Critical Infrastructure APAC, were proud to partner with PurePurge and Molecular Express on some incredibly important and exciting projects during Covid. With a unified goal of creating world class technologies in healthcare, together we helped Protecting Our Greatest Assets.
PurePurge™
From it's Southern California laboratories, PurePurge™ developed a patent-pending method of taking one of the most photo-sensitising substances available and rendering it transiently water soluble, resulting in an organic, photo-sensitive dye that can be deposited into or onto the surface of a vast range of substrates, fabrics and materials.
In collaboration with PurePurge™ CIAL partnered on several project feasibility studies, to collaboratively advance the applications of these technologies.
The development of a self-sanitising, anti-microbial and reusable N95 mask, with an enduring microbe deactivation capability.
Production of a hard surface and fabric sanitiser which will provide an enduring anti-microbial capability. Applications may include, medical environments, public transport seating and hard surfaces and other essential and or high risk public infrastructure.
A consumer and commercial washing liquid incorporating PurePurge™ technology which will deactivate microbes during the wash cycle, and remain within the fabric to provide enhanced anti-microbial protection to clothing, household and commercial linen and other daily wash and use fabrics.
Incorporating PurePurge™ technology into a polymer, which can then be applied or injection moulded and will provide an enduring anti-microbial capability for a finished surface/product. This could include door handles, seats, tabletops, etc and would be ideally suited to the medical and front line work environments.
Integration of PurePurge™ technology into a silicone and Thermoplastic Polyurethane (TPU) cover, which will provide an enduring anti-microbial capability for flexible covers associated with equipment where there may be considerable, changing human contact. This could include products such as keyboard covers, mechanical equipment joystick covers, control panel covers, etc.
Dr Gordon Wood
Gordon Wood is the CEO of PurePurge Inc, a medical professional and a lifelong entrepreneur in the healthcare sector. He is a fellow of the Royal College of Surgeons, holds a HND in Veterinary Sciences, and an HND in Biology. He spent his early career in cardiovascular clinical research where he successfully commercialised a new medical device. He has a strong track record of success in establishing and growing businesses involved in both the development and distribution of medical products and devices in both the public and private sectors. He has extensive international experience in the manufacture, distribution, and commercialisation of medical devices on a worldwide basis. Gordon has raised over USD 450,000,000 in investment capital. Gordon concurrently holds a number of executive, non-executive and advisory board positions.
MoLecular Express
Molecular Express, a subsidiary of Molecular GPS Technologies™ is a research and development technology company specialising in the application of life science technologies to address market needs across a broad spectrum of industries. The Company's lipid and "Molecular Guided Particle System" (Molecular GPS™) delivery platform is the basis for many active programs targeting anti-cancer therapeutics, drug delivery systems, vaccines, and nanoparticulate drug delivery technologies.
Molecular Express is applying the Molecular GPS™ technology platform to develop vaccines for influenza, herpes, HIV, Anthrax and A. fumigatus. In addition, studies demonstrate that the Molecular GPS™ technology platform can be used to develop a variety of therapeutics to combat cancers and emerging infectious diseases.
Currently, alongside Molecular Express Critical Infrastructure are in the knowledge gathering phase of several project feasibility studies to collaboratively advance the applications of these technologies.
These include:
The development of a universal respiratory pathogen vaccine, which will provide rapid protection against exposure to emergent respiratory disease pathogens such as the COVID-19.
Innovative use of the VesiVax® formulation technology to create a SARS-CoV vaccine that could potentially provide broad immunity against strains of SARS-CoV viruses such as SARS1 and SARS2, which is the cause of the current COVID-19 pandemic
Use of niclosamide nanoparticle formulations to create a series of anti-COVID-19 therapeutic products. Research indicates nanoparticle niclosamide formulations can alleviate or prevent the respiratory complications experienced by COVID-19 patients.
Dr Gary Fujii
As President and CEO of Molecular Express, Inc and Molecular GPS Technologies, I have an extensive background as a life scientist and entrepreneur with a focus on facilitating the translation of scientific discoveries from academia into the commercial sector. I am also an experienced biophysical chemist with expertise in developing and commercialising liposome-based products and have made major contributions to the use of protein/lipid complexes as drug delivery vehicles. As a creative entrepreneur, I have been responsible for a number of inventions (listed below) several of which have been turned into commercial products that are sold in diverse markets such as the speciality chemicals, cosmetics, and life sciences industries. The technologies and products that are being developed at Molecular Express leverage my previous experience developing and commercialising approved liposome products such as VesCan®, AmBisome® and DaunoXome®.
Dr Sam On Ho
As one of the senior managers at Molecular Express, I have been in leadership roles on multiple NIH proposals and contracts on vaccines and the development of therapeutics. I have been involved with various aspects of the preclinical studies of ME-101. I am excited to extend my experience with this product and the professional team that we have put together to apply this synthetic lung surfactant product to the current SARS-CoV-2 outbreak. I believe that the plan and team that we have put in place will fully support the research and development along with the possibility of manufacturing products in New Zealand for the region later this year.